Document is current

Article History

Received: 15 July 2025

Accepted: 7 August 2025

First Online: 27 August 2025

Declarations

:

: This study was approved by the Research Ethics Committee at the Hospital Universitario y Politécnico La Fe (Valencia, Spain) and was conducted in accordance with the Declaration of Helsinki on the ethical principles of medical research involving human subjects. Patients’ names, initials, or hospital numbers were not used.

: Alejandro Molina-Levya is an Editorial Board member of Dermatology and Therapy . Alejandro Molina-Levya was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Alejandro Molina-Leyva has received support for attending meetings, served as an advisory board member and participated in clinical trials from Abbvie, Novartis, Moonlake, MSD, Sanofi, Incyte Almirall and UCB. Eva Vilarrasa has received honoraria and/or travel grants and/or has served as an advisory board member and/or has participated in clinical trials sponsored by Abbvie, Aceleryn, Almirall, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Gebro, Incyte, Isdin, Janssen, Leo-Pharma, Lilly, Merck-Serono, MoonLake, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB. She also has worked as consultant or participated in clinical trials for iDermApp, Mediktor, DermUS, Biomi, HSCalc, BHH. Antonio Martorell has received honoraria and/or travel grants and/or has served as an advisory board member for Novartis, AbbVie, Janssen Cilag, UCB, Lilly, LEO Pharma, L’Oreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squibb, and Amgen. Additionally, AM has worked as a principal investigator in clinical trials supported by AbbVie, UCB, Janssen, Bristol Myers Squibb, Lilly, Galderma, Sanofi, and Novartis. Miguel Mansilla-Polo has received honoraria and/or travel grants and/or has served as an advisory board member for Novartis, UCB, Almirall, Sunpharma. Pablo Fernandez-Crehuet, Alberto Soto-Moreno and Fernando Alfageme- Roldán has received honoraria and/or travel grants and/or has served as an advisory board member for Novartis, Abbvie and UCB. Patricia Garbayo-Salmons declares honoraria for participating in advisory boards from Novartis and UCB; received support for attending meetings and/or travel from AbbVie, Amgen, Lilly, LEO Pharma, Novartis and UCB. Carmen García -Moronta received support from UCB and Novartis to attend scientific congresses. Laura Mahiques-Santos has received travel grants from Abbvie and has served as an advisory board member for Novartis. Irene Sánchez-Gutiérrez has received honoraria from Novartis and UCB. Gemma Martín-Ezquerra has received honoraria and/or travel grants from Novartis and has served as an advisory board member for UCB and Boehringer Ingelheim. Martí Pons-Benavent has received honoraria from Abbvie and Almirall. Rafael Fayos-Gregori, David Jiménez-Gallo, Lucía Aguilar-González and Begoña Escutia-Muñoz have nothing to disclose. Rebeca Alcala-García has provided scientific advice and participated in medical meetings and training courses sponsored by Almirall, Ferrer, Leo Pharma, Janssen, Novartis, Pierre Fabre, UCB, and participated as a principal investigator or collaborator in clinical trials or research projects for UCB. Antonio Sahuquillo-Torralba has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Novartis and Pfizer. Rafael Botella-Estrada has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by including AbbVie, Celgene, Janssen-Cilag, LEO, Pharma, Lilly, Novartis and Pfizer. Rafael Fayos-Gregori, David Jimenez-Gallo, Lucia Aguilar-Gonzalez and Begoña Escutia-Muñoz have nothing to disclose.